Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Signs Big Bang Deal With Aurobindo For Larger Presence in Generics; Biosimilars Next ?

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Pfizer has turned its attention to establishing a bigger presence in the U.S. for marketing generic drugs, terming it as an "engine of positive growth." The world's largest drug maker has signed a series of licensing agreements with India's Aurobindo Pharma to acquire rights of 39 generic solid oral dose products and 12 sterile injectable products
Advertisement

Related Content

With Seroquel Generic Approval, Is Aurobindo Close To Getting Off The FDA Hook?
Outsourcing Your Way Into Trouble: Pfizer Issues Recall After Indian Aurobindo Mislabels Bottles
Pfizer Signs MOU With Wuhan To Establish First R&D Center In Midwest China; Ranks Number One In China
Pfizer Ahead Of Guidance In India, President Of Established Products Business Unit David Simmons Tells PharmAsia News
Pfizer Leaps Into Japanese Generics Foray; Aims For 100 Generic Products By 2011
Pfizer Goes Big On Generic Injectables With Acquisition Of 15 Products From India’s Claris
Pfizer's Ambitions in the Off-Patent World
Pfizer/Wyeth Will Produce (Incremental) Growth, Pfizer Assures Investors
Merck Announces Major FOB Initiative With Its New Business Unit
Merck Announces Major FOB Initiative With Its New Business Unit
Advertisement
UsernamePublicRestriction

Register

SC071191

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel